- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06836232
En åpen pilotstudie av VTX2735 ved tilbakevendende perikarditt
En fase 2A, åpen pilotstudie for å evaluere sikkerhet/toleranse, effekt, farmakokinetikk og farmakodynamikk av VTX2735 hos deltakere med tilbakevendende perikarditt
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).
Cohort A will include approximately 10 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A
- A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A
- An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
Cohort B will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C
- A 14-day Follow-Up Period
Cohort C will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Ventyx Clinical Trial Contact
- Telefonnummer: ext 108 888-411-5176
- E-post: ClinicalTrials@ventyxbio.com
Studiesteder
-
-
-
Ghent, Belgia, 9000
- Rekruttering
- Local Site #056001
-
Leuven, Belgia, 3000
- Rekruttering
- Local Site #056002
-
-
-
-
-
Montreal, Canada, H4A 3J1
- Har ikke rekruttert ennå
- Local Site #840102
-
Ottawa, Canada, K1Y 4S7
- Rekruttering
- Local Site #840101
-
-
-
-
California
-
La Jolla, California, Forente stater, 92037
- Rekruttering
- Site Location #840023
-
Orange, California, Forente stater, 92868
- Rekruttering
- Local Site #840014
-
-
Florida
-
Saint Augustine, Florida, Forente stater, 32086
- Rekruttering
- Local Site #840016
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Local Site #840008
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Local Site #840010
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905-0002
- Rekruttering
- Local Site #840005
-
Hovedetterforsker:
- Sushil Luis
-
-
New York
-
New York, New York, Forente stater, 10032
- Rekruttering
- Local Site #840020
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Local Site #840017
-
-
Texas
-
Houston, Texas, Forente stater, 77034
- Rekruttering
- Local Site #840001
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Local Site #840019
-
Hovedetterforsker:
- Maan Malahfji
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84132
- Rekruttering
- Local Site #840013
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05401
- Rekruttering
- Local Site #840022
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- Local Site #840004
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- Local Site #840018
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Local Site #840021
-
-
-
-
-
Athens, Hellas, 11527
- Har ikke rekruttert ennå
- Local Site #300001
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants are male or female ≥ 18 years up to ≤ 75 years of age.
- Capable of giving signed informed consent and able to comply with the protocol
- Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
- Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
- CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
- Pericarditis pain score ≥ 4 based on the 11-point NRS.
- Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)
Exclusion Criteria:
- Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
- History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
- Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Kohort A
|
Dose A, Daily
Andre navn:
Dose B, Daily
Andre navn:
Dose C, Daily
Andre navn:
Dose D, Daily
Andre navn:
Dose E, Daily
Andre navn:
|
|
Eksperimentell: Kohort B -behandlingsgruppe B1
|
Dose A, Daily
Andre navn:
Dose B, Daily
Andre navn:
Dose C, Daily
Andre navn:
Dose D, Daily
Andre navn:
Dose E, Daily
Andre navn:
|
|
Eksperimentell: Kohort B -behandlingsgruppe B2
|
Dose A, Daily
Andre navn:
Dose B, Daily
Andre navn:
Dose C, Daily
Andre navn:
Dose D, Daily
Andre navn:
Dose E, Daily
Andre navn:
|
|
Eksperimentell: Cohort C Treatment Group C1
|
Dose A, Daily
Andre navn:
Dose B, Daily
Andre navn:
Dose C, Daily
Andre navn:
Dose D, Daily
Andre navn:
Dose E, Daily
Andre navn:
|
|
Eksperimentell: Cohort C Treatment Group C2
|
Dose A, Daily
Andre navn:
Dose B, Daily
Andre navn:
Dose C, Daily
Andre navn:
Dose D, Daily
Andre navn:
Dose E, Daily
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of VTX2735
Tidsramme: Day 1 of treatment period through study completion, up to 26 weeks
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation |
Day 1 of treatment period through study completion, up to 26 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Effect of VTX2735 on pericardial pain
Tidsramme: Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in Numeric Pain Rating Scale (NRS) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
|
Effect of VTX2735 on inflammation
Tidsramme: Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in High-Sensitivity C-Reactive Protein (hs-CRP) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 27930
- VTX2735-202 (Annen identifikator: Ventyx Biosciences, Inc.)
- J7W-MC-ELCA (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .